These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35442122)

  • 1. Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis.
    Strand V; Zhang L; Arnaud A; Connolly-Strong E; Asgarian S; Withers JB
    Expert Opin Biol Ther; 2022 Jun; 22(6):801-807. PubMed ID: 35442122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis.
    Strand V; Cohen SB; Curtis JR; Zhang L; Kivitz AJ; Levin RW; Mathis A; Connolly-Strong E; Withers JB
    Expert Rev Mol Diagn; 2022 Jan; 22(1):101-109. PubMed ID: 34937469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis.
    Curtis JR; Strand V; Golombek S; Zhang L; Wong A; Zielinski MC; Akmaev VR; Saleh A; Asgarian S; Withers JB
    Expert Rev Mol Diagn; 2022 Nov; ():1-10. PubMed ID: 36305319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility.
    Arnell C; Bergman M; Basu D; Kenney JT; Withers JB; Logan J; Harashima JL; Connolly-Strong E
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1734-1742. PubMed ID: 34669487
    [No Abstract]   [Full Text] [Related]  

  • 5. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.
    Cohen S; Wells AF; Curtis JR; Dhar R; Mellors T; Zhang L; Withers JB; Jones A; Ghiassian SD; Wang M; Connolly-Strong E; Rapisardo S; Gatalica Z; Pappas DA; Kremer JM; Saleh A; Akmaev VR
    Rheumatol Ther; 2021 Sep; 8(3):1159-1176. PubMed ID: 34148193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry.
    Sonomoto K; Fujino Y; Tanaka H; Nagayasu A; Nakayamada S; Tanaka Y
    Rheumatol Ther; 2024 Jun; 11(3):709-736. PubMed ID: 38637465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis.
    Curtis JR; Strand V; Golombek SJ; Karpouzas GA; Zhang L; Wong A; Patel K; Dines J; Akmaev VR
    Rheumatol Ther; 2024 Feb; 11(1):61-77. PubMed ID: 37948030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors.
    Hattori K; Hirano Y; Kanayama Y; Hattori Y; Kato T; Takahashi N; Ishiguro N; Kojima T
    Mod Rheumatol; 2021 Jan; 31(1):80-87. PubMed ID: 32148143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
    Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
    Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis.
    Jones A; Rapisardo S; Zhang L; Mellors T; Withers JB; Gatalica Z; Akmaev VR
    Expert Rev Mol Diagn; 2021 Nov; 21(11):1235-1243. PubMed ID: 34727834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
    Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset.
    Youssef P; Marcal B; Button P; Truman M; Bird P; Griffiths H; Roberts L; Tymms K; Littlejohn G
    J Rheumatol; 2020 Aug; 47(8):1174-1181. PubMed ID: 31787605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.